Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. (Nasdaq: MCRB) on May 20, 2021. The filing reports the appointment of a new senior executive officer and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the appointment of David Arkowitz as Executive Vice President, Chief Financial Officer, and Head of Business Development, effective on or about June 1, 2021. Mr. Arkowitz succeeds Marcus Chapman as the Company's principal financial officer and principal accounting officer. Mr. Chapman will remain with the Company as Senior Vice President, Finance.
Management Commentary and Compensation Details
The filing details the employment agreement entered into with Mr. Arkowitz, effective on his Commencement Date:
- Base Salary: $455,000 annually.
- Discretionary Bonus: Eligible for up to 40% of base salary.
- Sign-on Bonus: One-time cash payment of $50,000.
- Equity Awards:
- 270,000 stock options vesting over a standard four-year schedule.
- 5,000 restricted stock units (RSUs) vesting in a single installment one year after the grant date.
- Termination Provisions: In the event of termination without cause or resignation for good reason, Mr. Arkowitz is entitled to 12 months of base salary and continued medical coverage. In the event of a change in control within 60 days prior to or 12 months following such termination, he is entitled to accelerated vesting of equity, 12 months of base salary, continued medical coverage, and a lump sum equal to 1.0 times his target bonus.
Investor Verification Checklist
- Verify the exact commencement date of Mr. Arkowitz's employment (expected on or about June 1, 2021).
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause," "good reason," and "change in control."
- Confirm the fair market value of the common stock on the grant date to determine the exercise price of the 270,000 stock options.
- Monitor future filings for the transition of financial reporting responsibilities from Marcus Chapman to David Arkowitz.